MedTrace Logo

Safety of Wharton Jelly in Erectile Dysfunction

NCT02945449 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2018-11-15

No results posted yet for this study

Summary

Safety of Intracavernous injection of Wharton jelly Mesenchymal stem cells for the treatment of erectile dysfunction in diabetic patients.

Conditions

  • Erectile Dysfunction Associated With Type 2 Diabetes Mellitus

Interventions

BIOLOGICAL

Wharton Jelly Mesenchymal stem cells

Intracavernous injection of Wharton Jelly Mesenchymal stem cells.

Sponsors & Collaborators

  • Sophia Al-Adwan

    lead OTHER

Principal Investigators

  • Abdallah Awidi, MD · Cell Therapy Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-04
Primary Completion
2018-10-15
Completion
2018-11-30

Countries

  • Jordan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02945449 on ClinicalTrials.gov